Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study

References

• Beyer-Westendorf J, Camm AJ, Fox KAA, et al.; RIVER Registry Investigators. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: rivaroxaban evaluation in real life setting (river). Thromb J. 2019;17:7.
   Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3(1):28–36.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and safety of non-vitamin k oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018;118(3):526–538.
   PubMed Web of Science ®Google Scholar
• Martinez CAA, Lanas F, Radaideh G, et al.; XANTUS Investigators. Xantus-el: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J. 2018;70(4):307–313.
   Google Scholar
• Maura G, Billionnet C, Drouin J, et al. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin k antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016. BMJ Open. 2019;9(4):e026645.
   Web of Science ®Google Scholar
• Mazurek M, Huisman MV, Rothman KJ, et al.; GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the gloria-af phase ii registry. Thromb Haemost. 2017;117(12):2376–2388.
   PubMed Web of Science ®Google Scholar
• Mueller T, Alvarez-Madrazo S, Robertson C, et al. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019;85(2):422–431.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Pottegard A, Grove EL, Hellfritzsch M. Use of direct oral anticoagulants in the first year after market entry of edoxaban: a Danish nationwide drug utilization study. Pharmacoepidemiol Drug Saf. 2018;27(2):174–181.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Gao H, Shrader P, et al.; ORBIT-AF Investigators. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the garfield-af, orbit-af i, and orbit-af ii registries. Am Heart J. 2017;194:132–140.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants vs warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:2505.
   PubMed Web of Science ®Google Scholar
• Lixiana: Epar – product information. European Medicines Agency; 2015 [Updated 2019 Jul 10, Accessed 2019 Aug 28]. https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf
   Google Scholar
• De Caterina R, Kelly P, Monteiro P, et al.; ETNA-AF-Europe investigators. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (af) in Europe (ETNA-AF-Europe). BMC Cardiovasc Disord. 2019;19(1):165.
   Google Scholar
• De Caterina R, Kelly P, Monteiro P, et al.; ETNA-AF-Europe investigators. Design and rationale of the edoxaban treatment in routine clinical practice for patients with atrial fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med (Hagerstown). 2019;20(2):97–104.
   PubMed Web of Science ®Google Scholar
• Hanemaaijer S, Sodihardjo F, Horikx A, et al. Trends in antithrombotic drug use and adherence to non-vitamin k oral anticoagulants in the Netherlands. Int J Clin Pharm. 2015;37(6):1128–1135.
   PubMed Web of Science ®Google Scholar
• van den Heuvel JM, Hovels AM, Buller HR, et al. Noacs replace vka as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in the Netherlands. Thromb J. 2018;16:7.
   PubMed Web of Science ®Google Scholar
• Moudallel S, Steurbaut S, Cornu P, et al. Appropriateness of doac prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol. 2018;9:1220.
   PubMed Web of Science ®Google Scholar
• Santos J, Antonio N, Rocha M, et al. Impact of direct oral anticoagulants off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86(3):533–547.
   PubMed Web of Science ®Google Scholar
• Arbel R, Sergienko R, Hammerman A, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med. 2019;132(7):847–855.e843.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Pieper K, et al. Frequency and outcomes of reduced dose non-vitamin k antagonist anticoagulants: results from orbit-af ii (the outcomes registry for better informed treatment of atrial fibrillation ii). J Am Heart Assoc. 2018;7(4): pii: e007633.
   Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin k antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor xa activity, and outcomes: an analysis of data from the randomised, double-blind engage af-timi 48 trial. Lancet. 2015;385(9984):2288–2295.
   PubMed Web of Science ®Google Scholar
• Stacy ZA, Call WB, Hartmann AP, et al. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther. 2016;5(1):1–18.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al.; ESC Scientific Document Group. The 2018 European heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• Tjin-A-Tsoi TBPM. The Netherlands on a European scale 2019. Statistics Netherlands (CBS). 2019 [accessed 28 Feb 2020]. https://longreads.cbs.nl/european-scale-2019/
   Google Scholar